Formulary Exception vs Prior Authorization: Choosing the Right Request

Which Request to File from the Current Formulary Page

When a high-cost specialty therapy encounters a point-of-sale claim rejection at the dispensing pharmacy, market access navigators, hub intake coordinators, and specialty pharmacy technicians face an immediate administrative crossroads. Web portals deployed by commercial health plans and pharmacy benefit managers (PBMs) frequently label every override transaction with the generic banner of "prior authorization." That operational shorthand obscures a fundamental legal and procedural divide established by federal health program regulations and commercial benefit designs.

Filing the wrong request type can delay a specialty fill because the documentation, statutory clock, and approval test are not the same. A standard prior authorization (PA) submission is a coverage determination where the prescriber asserts that the enrollee satisfies the plan’s published clinical, diagnostic, and step-therapy criteria. Conversely, a formulary exception request asks the health plan to waive published utilization management (UM) requirements—such as fail-first step edits, quantity limits, or dosing restrictions—or to cover an off-formulary drug that is entirely omitted from the plan’s active drug list. Each track demands different clinical documentation, triggers a distinct statutory review clock, and applies an unequal legal threshold for approval.

The initial procedural step is establishing whether the drug is being billed through the medical benefit or the pharmacy benefit. For provider-administered infused biologics, teams must execute an upfront Benefit verification for specialty drugs: medical vs pharmacy benefit to distinguish Medicare Part B or commercial medical policies from retail pharmacy benefit rules. As teams prepare for emerging interoperability standards and Electronic prior authorization readiness for specialty drugs in 2027, recognizing the boundaries between meeting published criteria and petitioning for an exception remains the linchpin of clean claim adjudication.

flowchart TD
    A["Prescription Rejected at Pharmacy Counter"] --> B{"Is Product on Active Formulary / PDL?"}
    B -- "Listed on Formulary" --> C{"Subject to Utilization Management (PA/ST/QL)?"}
    C -- "No UM Edits" --> D["Resolve Pharmacy Billing / Tier Copay Issue"]
    C -- "Yes (PA / ST / QL)" --> E{"Does Patient Meet Published Plan Criteria?"}
    E -- "Yes (Criteria Met)" --> F["File Prior Authorization (Satisfy PA)"]
    E -- "No (Contraindication / Step Failure)" --> G["File Formulary Exception (Waive UM)"]
    B -- "Not on Formulary" --> H{"Is Indication a Statutory Excluded Use?"}
    H -- "Yes (§ 1927(d)(2) Exclusion)" --> I["Benefit Coverage Dispute / Commercial Bridge"]
    H -- "No (Medically Accepted Indication)" --> J["File Non-Formulary Exception Request"]

To establish baseline operational clarity across federal and commercial programs, the following classification matrix defines the governing rules, required clinical documentation, and statutory adjudication clocks for each core coverage request category.

Source-Document Workflow: Program, Benefit, Listing Status

A dependable market access intake process never starts within an electronic portal or payer clearinghouse. It begins by examining the primary source documents that establish the patient’s legal rights and the plan’s published utilization rules. Access teams must execute a three-step source-document triage before generating an appeal or authorization packet.

Step 1: Determine Benefit Routing and Administration Setting. Verify whether the medication falls under the pharmacy benefit (self-administered subcutaneous, oral, or inhaled specialty drugs) or the medical benefit (physician-administered IV infusions or in-clinic injectables). In Medicare Advantage, medical drug utilization management is governed by Medicare Part C organization determination rules under 42 CFR Part 422 Subpart M, which follow different adjudication procedures than Part D pharmacy benefits. Commercial fully insured plans evaluate medical injectable authorizations against clinical medical necessity guidelines rather than outpatient formulary tiers. Do not apply outpatient pharmacy exception rules to a buy-and-bill medical claim.

Step 2: Identify the Governing Regulatory Program. Inspect the patient’s insurance card, Evidence of Coverage (EOC), or Summary of Benefits and Coverage (SBC). The regulatory machinery governing exceptions varies across health plan archetypes:

• Medicare Part D (PDP or MA-PD): Strictly governed by 42 CFR Part 423 Subpart M and CMS manual guidance. The satisfy-versus-waive test, statutory supporting statement criteria, and tolling windows apply exclusively here.

• ACA Essential Health Benefit Plans: Non-grandfathered individual and small-group commercial health plans are governed by 45 CFR § 156.122(c). Standard determinations are tied directly to request receipt, and approved exceptions remain valid for the full duration of the prescription.

• Medicaid Fee-for-Service and Managed Care: Covered outpatient drugs are regulated by Social Security Act § 1927 and 42 CFR § 438.210(d)(3). Medicaid programs generally utilize a single "prior authorization" vehicle to handle both clinical criteria reviews and non-preferred PDL overrides, backed by a federal 24-hour response mandate.

• Commercial Large-Group and Self-Funded ERISA Plans: Self-funded employer plans governed by the Employee Retirement Income Security Act (ERISA) are not automatically bound by 45 CFR § 156.122 unless the plan design expressly incorporates state benchmark EHB standards. Coverage and exception mechanisms depend entirely on the employer’s specific plan document and summary plan description (SPD).

Step 3: Audit Current Dated Formulary Documents. Retrieve the active, dated formulary document, comprehensive drug list, or Preferred Drug List directly from the health plan’s regulatory portal. Verify the exact version date, as mid-year formulary changes and monthly HPMS updates frequently alter utilization tags. Confirm whether the target molecule is:

1. Listed with Utilization Management: Tagged with "PA" (Prior Authorization), "ST" (Step Therapy), or "QL" (Quantity Limit). Check the matching clinical criteria document to verify whether the patient satisfies the requirements or requires an exception.

2. Off-Formulary / Non-Listed: Completely omitted from the formulary listing. This requires an off-formulary exception under 42 CFR § 423.578(b) or 45 CFR § 156.122(c).

3. Statutorily Excluded from Part D: Excluded under 42 CFR § 423.100 and Social Security Act § 1927(d)(2). An exception cannot be granted for an excluded use.

Medicare Part D: Satisfy PA versus Waive UM versus Non-Formulary

In Medicare Part D, the regulatory taxonomy of coverage requests is grounded in 42 CFR § 423.566. Under § 423.566(b), a coverage determination includes: (1) a decision not to provide or pay for a Part D drug, including because it is not on the formulary, is not medically necessary, was furnished out of network, or is otherwise excludable under section 1862(a) of the Act if applied to Part D; (2) failure to provide a coverage determination in a timely manner when delay would adversely affect the enrollee’s health; (3) a decision on a tiering exception under § 423.578(a); (4) a decision on a formulary exception under § 423.578(b); and (5) a decision on the amount of cost sharing. CMS’s July 6, 2026 guidance § 40.2 also treats a decision on whether an enrollee has satisfied a prior-authorization or other utilization-management requirement as an initial determination. Both a satisfy-PA coverage determination and a formulary exception are coverage determinations; they occupy separate statutory lanes. Presentation of a prescription at the pharmacy is not, by itself, a coverage-determination request unless the sponsor chooses to treat it as one; network pharmacies must still distribute the CMS pharmacy notice of the right to request a coverage determination.

The operational standard governing this distinction was reinforced in CMS’s Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance (effective July 6, 2026). In Section 40.4 (Part D Only), CMS establishes an explicit operational test: plan sponsors must differentiate between requests where the enrollee is attempting to satisfy published prior authorization criteria, and requests where the enrollee is petitioning the sponsor to waive those criteria.

“Plan sponsors must determine whether a request that involves PA or other UM requirement is either a coverage determination (or redetermination) request where an enrollee is attempting to satisfy a PA requirement, or an exception request where the enrollee is asking the plan sponsor to waive a PA requirement. If the plan sponsor does appropriate outreach and is still unable to determine if the enrollee/prescriber is asking for an exception to the PA criteria (meaning the person was unresponsive to the request), the case should be treated as an attempt to satisfy the PA criteria.” — CMS Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance (effective July 6, 2026), § 40.4 (Part D Only). CMS publishes the PDF from a public appeals page; the fetched file also carries an internal-use banner, so public HTML Exceptions and Coverage Determinations pages remain the preferred reader-facing citations where they overlap.

This administrative default is operationally important. When outreach still cannot tell whether the enrollee or prescriber is asking to waive PA, guidance § 40.4 says the case should be treated as an attempt to satisfy published PA criteria. If the file does not meet those criteria, that classification starts the request-receipt clock rather than the supporting-statement clock and will be judged against the published PA test. Explicitly framing the submission as an exception request under 42 CFR § 423.578(b), with the required supporting statement, is what puts the file on the waive-UM track.

Under 42 CFR § 423.578(b), formulary exceptions encompass two separate scenarios: requesting an off-formulary drug, or requesting that a plan sponsor waive utilization management tools. The regulation explicitly identifies cost-utilization tools—including dose restrictions and step-therapy requirements—as falling within the scope of formulary exceptions. Furthermore, CMS Guidance Section 40.5.2 provides a critical structural clarification: a drug subject to utilization management remains a formulary drug; an unmet UM edit does not transform it into an off-formulary drug. Navigators must not file off-formulary exception paperwork for a product that is already listed on the plan’s formulary with step edits.

When petitioning for a formulary exception under § 423.578(b), the submission must contain a prescriber supporting statement meeting the strict statutory criteria of 42 CFR § 423.578(b)(5). The physician or prescriber must attest orally or in writing that the requested drug is medically necessary because at least one of the following clinical conditions is met:

• All Covered Alternatives Ineffective or Harmful (§ 423.578(b)(5)(i)): All covered Part D drugs on any tier for the treatment of the same condition would not be as effective as the requested drug, would have adverse effects, or both.

• Step-Therapy / Form Alternative Failure (§ 423.578(b)(5)(ii)): The prescription drug alternative(s) listed on the formulary or required to be used in accordance with step therapy requirements has been ineffective in treating the enrollee’s disease or medical condition, or, based on both sound clinical evidence and medical and scientific evidence and the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug’s effectiveness or patient compliance; or has caused, or based on sound clinical evidence and medical and scientific evidence is likely to cause, an adverse reaction or other harm to the enrollee.

• Dose Restriction / Quantity Limit Ineffective (§ 423.578(b)(5)(iii)): The number of doses available under a dose restriction for the requested drug has been ineffective in treating the enrollee’s disease or medical condition, or, based on both sound clinical evidence and medical and scientific evidence and the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug’s effectiveness or patient compliance.

Prescribers must substantiate these claims with objective medical history. In specialty immunology and metabolic medicine, teams should consult standardized clinical evidence frameworks, such as Step therapy exception evidence for specialty drugs and published GLP-1 step therapy exception: document contraindication and prior-therapy failure, to ensure chart notes document contraindications, severe intolerances, or previous therapeutic failures with undeniable precision.

Clocks, Supporting Statements, and the Model Form Checkboxes

One of the most consequential operational differences between filing a standard prior authorization and submitting a formulary exception lies in how the legal adjudication clock is triggered. Misunderstanding these clock rules causes access teams to issue premature appeal escalations or miss critical tolling deadlines.

For a standard Part D coverage determination that is not an exception (attempting to satisfy published PA criteria), 42 CFR § 423.568(b) mandates that the sponsor notify the enrollee and prescriber of its determination as expeditiously as the enrollee’s health requires, but no later than 72 hours after receipt of the request. If the standard timeframe could seriously jeopardize the enrollee’s life, health, or ability to regain maximum function, 42 CFR § 423.570 governs whether the request is expedited, and 42 CFR § 423.572(a) requires an expedited determination within 24 hours after receipt of the request.

In stark contrast, for a formulary or tiering exception, 42 CFR § 423.568(b) dictates that the 72-hour standard clock does not begin upon receipt of the request form; it begins upon receipt of the prescriber’s supporting statement. If an enrollee or representative files an exception request without an accompanying physician supporting statement, the plan sponsor cannot immediately deny the case. Instead, federal regulations enforce a mandatory 14-calendar-day tolling window. The sponsor must hold the case open for up to 14 days while conducting outreach to secure the statement. If no supporting statement is received by the expiration of 14 calendar days, the sponsor must issue its determination within 72 hours from the close of that 14-day window.

Under CMS Guidance Section 40.5.3, once any verbal or written statement indicating medical necessity is received from the prescriber, the exception clock starts immediately, even if the sponsor considers the clinical rationale incomplete. Plans are strictly prohibited from tolling or extending the statutory timeframe once a written supporting statement has been logged. Furthermore, sponsors cannot extend review timelines by dispensing a transition supply.

When preparing a written submission in Medicare Part D, navigators frequently utilize the standard CMS Model Coverage Determination Request Form. The form provides a series of "Type of Request" checkboxes that constitute the public administrative taxonomy for Part D coverage determinations. Matching your clinical argument to the correct checkbox is vital.

Tiering Exceptions and Statutory Excluded Uses

Two areas of persistent confusion among clinical practices and access navigators are the boundaries of tiering exceptions and the legal consequences of statutory excluded uses. Conflating these mechanisms with standard formulary exceptions produces immediate administrative rejections.

Tiering Exceptions Under 42 CFR § 423.578(a). A tiering exception is an entirely separate administrative remedy from a formulary exception. While a formulary exception seeks coverage for an off-formulary drug or waives a utilization management restriction, a tiering exception accepts that the drug is already covered on the formulary, but petitions the plan to provide it at the lower cost-sharing terms applicable to preferred alternatives. To secure a tiering exception under § 423.578(a)(4), the prescriber must certify that preferred drugs on the lower tier would not be as effective, would cause adverse effects, or both.

However, critical regulatory guardrails severely restrict tiering exceptions:

• Specialty Tier Protection: Beginning January 1, 2022, CMS regulations allow Part D sponsors with one or two specialty tiers to design their exceptions process such that specialty-tier drugs are ineligible for tiering exceptions down to non-specialty tiers. If the sponsor has designed that limit, a specialty-tier biologic is not eligible for a tiering exception to a non-specialty tier.

• Brand-to-Generic and Biologic Boundaries: Under § 423.578(a)(1), plan sponsors are not required to grant a tiering exception for a brand-name drug down to a preferred tier populated exclusively by generic drugs. Similarly, biological products need not be excepted down to a tier consisting solely of non-biological alternatives.

• The Non-Formulary Tiering Ban: Under 42 CFR § 423.578(c)(4)(iii), an off-formulary drug approved via a formulary exception is legally barred from receiving a tiering exception. CMS guidance § 40.5.2 states that the regulation does not prescribe which existing tier’s cost sharing applies to an approved non-formulary exception; the sponsor chooses a single cost-sharing level that already exists on the formulary (and may use a second, lower existing-tier level for generic exception approvals, applied uniformly). The sponsor may not invent a special exception-only tier. The enrollee still cannot obtain a tiering exception on that approved non-formulary drug.

• The UM-Exception Synergy: Conversely, CMS Guidance Section 40.5.2 establishes that because a formulary drug subject to utilization management remains a formulary drug, an enrollee who successfully obtains an exception waiving a step edit or PA edit remains eligible to request a subsequent tiering exception for that same formulary drug (provided the drug is not on an exempt specialty tier).

Statutory Excluded Uses vs. Formulary Omissions. Under 42 CFR § 423.578(e), federal law dictates that “Nothing in this section may be construed to allow an enrollee to use the exceptions processes set out in this section to request or be granted coverage for a prescription drug that does not meet the definition of a Part D drug.” This statutory wall separates a routine formulary omission from a statutory exclusion.

Under 42 CFR § 423.100 and CMS Prescription Drug Benefit Manual Chapter 6 (Section 20.1), the definition of a Part D drug explicitly excludes any drug or medical use that is excluded or restricted under Section 1927(d)(2) of the Social Security Act (except smoking-cessation agents). Statutory excluded categories include:

1. Agents when used for anorexia, weight loss, or weight gain, even if prescribed for a severe non-cosmetic medical purpose such as morbid obesity.

2. Agents when used to promote fertility, or for cosmetic purposes and hair growth.

3. Agents used for symptomatic relief of cough and colds, most prescription vitamin and mineral products (except prenatal vitamins and fluoride preparations), and non-prescription over-the-counter (OTC) medications.

4. Drugs covered under Medicare Part A or Part B for that specific individual in that specific setting.

Finally, when a Part D formulary exception is approved, 42 CFR § 423.578(c)(4) says the sponsor may not require the enrollee to request approval for a refill or a new prescription to continue the drug for the rest of the enrollment period, so long as the prescriber continues to prescribe it, it continues to be considered safe for the condition, and the enrollment period has not expired. The sponsor must not create a special cost-sharing tier that applies only to exception-approved drugs. Costs of a covered non-formulary drug count toward the annual out-of-pocket threshold under § 423.578(b)(3). If the enrollee renews membership, continuation into the next plan year is optional, not automatic. Guidance § 40.5.5 adds that if the exception will not continue into the next plan year, the sponsor must send written notice at least 60 days before year-end unless the original approval already stated the end date. A supporting statement is still not an automatic approval under § 423.578(f).

ACA EHB, Medicaid PDL, and Medical-Benefit Routing

While Medicare Part D provides the most codified regulatory structure, specialty market access teams frequently navigate commercial Affordable Care Act (ACA) marketplace plans, state Medicaid programs, and employer-sponsored benefits. Importing Medicare rules into these programs produces procedural failure.

ACA Essential Health Benefit (EHB) Exceptions (45 CFR § 156.122(c)). Non-grandfathered individual and small-group health plans that are legally required to provide Essential Health Benefits must operate an explicit drug exception process under 45 CFR § 156.122(c). This federal standard allows an enrollee, representative, or prescriber to request access to clinically appropriate drugs that are not otherwise covered on the plan’s formulary.

• Clock Trigger Tied to Request: Unlike Medicare Part D, the ACA adjudication clock begins immediately upon receipt of the request. A standard determination must be rendered within 72 hours of request receipt. If the patient experiences exigent circumstances—defined as a health condition that may seriously jeopardize life, health, or ability to regain maximum function, or when an enrollee is on a current course of treatment using a non-formulary drug—the plan must issue an expedited determination within 24 hours of request receipt.

• Mandatory Coverage Duration: Under 45 CFR § 156.122(c)(1)(iii), an approved standard exception remains valid for the full duration of the prescription, including refills. An approved expedited exception remains valid for the duration of the exigency.

• EHB Treatment and Cost-Sharing Accumulation: A granted exception must be treated as an Essential Health Benefit, meaning that all enrollee cost sharing must count toward the annual limitation on cost sharing under 45 CFR § 156.130.

• Independent External Review: If an ACA health plan denies an exception request, 45 CFR § 156.122(c)(3) requires an external exception review path conducted by an independent review organization (IRO), with binding 72-hour (standard) and 24-hour (expedited) turnaround clocks.

Medicaid Preferred Drug Lists and the 24-Hour Mandate. In state Medicaid programs—both Fee-for-Service (FFS) and Medicaid Managed Care Organizations (MCOs)—the operational architecture diverges completely. Under Section 1927(d)(5)(A) of the Social Security Act and 42 CFR § 438.210(d)(3), any state prior authorization program for covered outpatient drugs must provide a response by telephone or other telecommunication device within 24 hours of receiving the request.

State Medicaid agencies routinely structure their Preferred Drug Lists (PDLs) such that any non-preferred medication is subjected to "prior authorization." In this environment, filing a "prior authorization" for a non-preferred drug is the formal legal mechanism to obtain an exception to the PDL. Access specialists must not import Medicare’s "do not file PA for an off-formulary drug" rule into Medicaid; instead, navigators must complete the state’s designated Non-Preferred Drug PA Form, substantiating clinical failure, contraindication, or intolerance to preferred PDL alternatives. As states enact aggressive prior authorization legislation, teams should track local compliance through the State prior authorization reform tracker for specialty drug access.

Crucially, 42 CFR § 438.210(d)(3) exempts covered outpatient drugs from the general Medicaid service authorization timeframes (such as the standard 7-calendar-day authorization clock taking effect in 2026). Furthermore, under 42 CFR § 438.210(f), public reporting metrics for prior authorization explicitly exclude prescription drug data. When Medicaid access barriers persist, navigators often transition qualified patients to independent Patient assistance and prior authorization belong in the same workflow to mitigate financial toxicity.

Medical-benefit and Medicare Part B drug requests are organization determinations, not Part D formulary exceptions. The July 6, 2026 guidance applies 42 CFR Part 422, Subpart M to Part C organization determinations, including prior authorization and step therapy for Part B drugs, and Part 423, Subpart M to Part D coverage determinations. A buy-and-bill or medical-benefit PA uses the medical-benefit policy and, for Medicare Advantage, organization-determination timeframes; it is not classified by the Part D model-form checkboxes. Route medical versus pharmacy benefit before choosing PA versus exception.

Worked Fictional Request-Choice Record

To anchor these regulatory concepts in daily operational practice, the following dated source-document worksheet illustrates how specialty access teams should classify incoming pharmacy rejections. The worksheet traces three distinct clinical scenarios across benefit verification, document inspection, request selection, and appeal routing.

Operational Analysis of Case 1: In Case 1, the product is listed on the Part D formulary, and the patient’s medical chart contains documented evidence of adequate therapeutic trial and failure on the required prerequisite agent. Filing a coverage determination to satisfy published prior authorization criteria is the clean, legally sound approach. Filing an exception request here would misclassify the file, potentially delaying review while the sponsor awaits a § 423.578 supporting statement that is legally superfluous.

Operational Analysis of Case 2: In Case 2, the enrollee cannot satisfy the plan’s published step-therapy algorithm because the required first-line agent caused documented organ toxicity. If the clinic submits a standard PA packet that tries to prove the published step was completed, the file is being judged against criteria the enrollee cannot meet. By checking the posted CMS model-form box for an exception to the requirement to try another drug and attaching a signed § 423.578(b)(5) supporting statement detailing the prior adverse drug reaction, the team invokes the statutory waiver process.

Operational Analysis of Case 3: In Case 3, the medication is omitted entirely from an ACA Marketplace formulary. Filing a prior authorization form for an off-formulary drug will prompt the clearinghouse to reject the transaction as an invalid product code. Navigators must initiate a formal EHB exception under 45 CFR § 156.122(c). Once approved, 45 CFR § 156.122 requires the plan to treat the excepted drug as an Essential Health Benefit, including counting enrollee cost-sharing toward the annual limitation under § 156.130, and to cover a granted standard exception for the duration of the prescription, including refills.

Labeled fictional Part D non-formulary packet (not a real member, NDC, or coverage outcome): as-of 2026-09-20; standalone Part D PDP; pharmacy benefit; current comprehensive formulary PDF omits the prescribed Part D drug entirely; matching PA-criteria document does not apply because the product is not listed. Request type: formulary exception for an off-formulary Part D drug under 42 CFR § 423.578(b), not a satisfy-PA coverage determination. Clock: 72 hours standard or 24 hours expedited from receipt of the prescriber supporting statement, with up to 14 calendar days of tolling if the statement has not arrived. Posted CMS model-form checkbox: “I need a drug that is not on the plan’s list of covered drugs (formulary exception).” Required showing: 42 CFR § 423.578(b)(5)(i)—all covered Part D drugs on any tier for the same condition would not be as effective, would have adverse effects, or both. Do not file the plan’s PA form as if it applied to a product the current formulary does not list. First appeal path if adverse: Part D redetermination. This worksheet is fictional process mapping and is not patient-specific medical, reimbursement, or financial advice.

Sources

This operational guide is established upon authoritative federal health program regulations, Centers for Medicare & Medicaid Services guidance manuals, and statutory public health provisions:

• CMS Medicare Prescription Drug Exceptions Overview: Guidance on Part D formulary and tiering exception standards, prescriber supporting statement mandates, and adjudication timeframes.

• CMS Medicare Coverage Determinations Guidelines: Administrative rules defining standard coverage determinations, expedited criteria, and direct member reimbursement timeframes.

• CMS Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance (effective July 6, 2026): Section 40.4 operational test for satisfying versus waiving PA, Section 40.5 exception processing standards, and Section 30.1.1 excluded drug provisions.

• 42 CFR § 423.566 — Coverage Determinations: Electronic Code of Federal Regulations listing the statutory scope of Medicare Part D coverage determinations and appealable actions.

• 42 CFR § 423.568 — Standard Timeframe and Notice Requirements: Federal requirements governing 72-hour coverage determination timeframes, exception clock triggers, and 14-day tolling rules.

• 42 CFR § 423.570 — Expediting Certain Coverage Determinations: When a coverage-determination request may be expedited. The 24-hour notice clock itself is in 42 CFR § 423.572(a).

• 42 CFR § 423.578 — Exceptions Process: Governing federal statute for tiering exceptions, formulary exceptions, utilization management waivers, and supporting statement content.

• 42 CFR § 423.100 — Definitions of Part D Drugs: Regulatory definition of covered Part D drugs, excluding Part A/B covered items and Section 1927(d)(2) statutory excluded categories.

• 42 CFR § 423.120 — Access to Covered Part D Drugs: Statutory standards for P&T formulary development, utilization management rules, and mandatory transition fill supplies.

• CMS Medicare Prescription Drug Benefit Manual, Chapter 6: Policy manual detailing Part D formulary design, transition fill operations, and non-covered drug exclusions.

• CMS Model Coverage Determination Request Form: Standardized model form establishing the operational taxonomy for prior authorization, exceptions, and reimbursement requests.

• 45 CFR § 156.122 — ACA Essential Health Benefits Prescription Drug Standards: Federal regulations mandating the standard 72-hour and expedited 24-hour exception processes for commercial marketplace health plans.

• Social Security Act § 1927 — Payment for Covered Outpatient Drugs: Statutory provisions establishing Medicaid drug rebate requirements, covered outpatient drug authorizations, and the 24-hour telecommunication response mandate.

• 42 CFR § 438.210 — Medicaid Managed Care Coverage and Authorization: Regulations governing Medicaid MCO authorization procedures, drug authorization carve-outs, and prior authorization metric exclusions.